Cognition Therapeutics is a drug discovery company using proprietary and biologically-relevant screening and chemistry platforms to closely model the pathology of neurodegenerative diseases. The company’s lead program is focused on the discovery of small molecule therapeutics that block the action of the toxic soluble oligomer proteins that cause the cognitive decline associated with Alzheimer’s disease (AD). This program has identified first-in-class drugs that selectively block soluble Abeta oligomer-induced toxicity on synapse function. These drugs are expected to be disease modifying for Alzheimer’s disease.
Cognition Therapeutics — IPO in 2021 (3x multiple)Arash Sani2022-03-02T10:20:17-08:00